Reuters news agency reported on Wednesday that according to a source, Serum Institute of India has received Indian regulatory approval, from the Drugs Controller General of India, to resume local clinical trials of British pharmaceutical company AstraZeneca's potential COVID-19 vaccine.
Reportedly, AstraZeneca has resumed British clinical trials of the vaccine, considered one of the most advanced in development for COVID-19, after they were paused earlier this month following a serious side effect in a trial participant.
Trials have also resumed in Brazil and South Africa.
However, the trial remains on hold in the US, as confirmed by the US Food and Drug Administration on 15 September 2020.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML